Firms

BiomedVC

Elisabethenanlage 11, 4051 Basel, Switzerland

BiomedVC AG is a Swiss life-sciences venture manager established in 2021 to continue the investment legacy of the separate BioMedPartners AG. It supports scientific founders building venture-backed biotechnology companies, typically entering at seed or SeriesA and reserving capital for subsequent rounds. Its geographic emphasis is continental Europe, particularly Switzerland and Germany. The own current public directory identifies six core investment/finance staff and five venture partners or entrepreneurs in residence; Michael Wacker, Valentin Piëch and Stefan Fäs have explicitly dual manager affiliations. The successor is a distinct Swiss legal corporation, CHE-465.445.585, with its own 2023 statutory board notice, and not a renamed 2020 Noema buyer. The European Investment Fund identifies its actual legal fund as BiomedInvest IV SCSp, RAIF. Own site confirms an initial close but does not disclose its closed size or exact day; April16,2026 own release says it is advancing toward a second close. The widely reported CHF150M is a target, not a verified final fund close. New FundIV investments on the own portfolio include T-CURX, iDEL Therapeutics, Scenic Biotech, Dimericon and Dolthera, with research in advanced therapeutic platforms and genetic mechanisms. The inherited combined website also lists many BioMedInvestI–III companies; these are not automatically assigned to the successor’s investment ledger. The primary scientific investment focus is biotechnology and therapeutic development; AI or neuroscience eligibility is limited to actual relevant portfolio research rather than a generic label for every pharmaceutical company. Its authentic current own corporate wordmark and all published named operating-team portraits were retrieved from exact primary WordPress asset URLs. Board member Nadia Tarolli Schmidt is separately confirmed by her current outside listed-company biography; Ulrich Vischer’s legal-chair record belongs the earlier manager, with historical-source scope.

Founded: 2021
Type: Venture capital